Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mood Effects of Low-Dose LSD in Healthy Volunteers
NCT03790358Phase 1Completed
- Sponsor
- University of Chicago
- Start
- May 2018
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of Lysergide in major depressive disorder (MDD) (4 arms), sponsored by University of Chicago. Primary endpoint: Profile of Mood States at 8 weeks. Started May 2018; status: completed.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03790358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790358.